S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
CGC   18.41 (-9.27%)
BABA   186.78 (+1.04%)
GE   11.55 (+0.17%)
T   37.75 (+0.40%)
ACB   2.70 (-13.46%)
F   8.89 (+2.07%)
PRI   130.63 (+0.14%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
CGC   18.41 (-9.27%)
BABA   186.78 (+1.04%)
GE   11.55 (+0.17%)
T   37.75 (+0.40%)
ACB   2.70 (-13.46%)
F   8.89 (+2.07%)
PRI   130.63 (+0.14%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
CGC   18.41 (-9.27%)
BABA   186.78 (+1.04%)
GE   11.55 (+0.17%)
T   37.75 (+0.40%)
ACB   2.70 (-13.46%)
F   8.89 (+2.07%)
PRI   130.63 (+0.14%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
CGC   18.41 (-9.27%)
BABA   186.78 (+1.04%)
GE   11.55 (+0.17%)
T   37.75 (+0.40%)
ACB   2.70 (-13.46%)
F   8.89 (+2.07%)
PRI   130.63 (+0.14%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
Log in

Amarin Stock Price, Forecast & Analysis (NASDAQ:AMRN)

$20.91
+0.39 (+1.90 %)
(As of 11/22/2019 04:00 PM ET)
Today's Range
$20.25
Now: $20.91
$21.10
50-Day Range
$13.97
MA: $17.23
$24.21
52-Week Range
$11.78
Now: $20.91
$24.67
Volume6.08 million shs
Average Volume8.20 million shs
Market Capitalization$7.47 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.14
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AMRN
CUSIPN/A
Phone353-1669-9020

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$229.21 million
Book Value$1.61 per share

Profitability

Net Income$-116,440,000.00

Miscellaneous

EmployeesN/A
Market Cap$7.47 billion
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive AMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter.


Amarin (NASDAQ:AMRN) Frequently Asked Questions

What is Amarin's stock symbol?

Amarin trades on the NASDAQ under the ticker symbol "AMRN."

How were Amarin's earnings last quarter?

Amarin Co. plc (NASDAQ:AMRN) announced its earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.03. The biopharmaceutical company earned $112.40 million during the quarter, compared to analyst estimates of $110.04 million. Amarin had a negative net margin of 17.42% and a negative return on equity of 26.67%. Amarin's revenue for the quarter was up 104.4% on a year-over-year basis. During the same period in the previous year, the business posted ($0.08) earnings per share. View Amarin's Earnings History.

When is Amarin's next earnings date?

Amarin is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Amarin.

What price target have analysts set for AMRN?

12 brokerages have issued 12 month price objectives for Amarin's shares. Their forecasts range from $7.00 to $51.00. On average, they expect Amarin's share price to reach $27.73 in the next twelve months. This suggests a possible upside of 32.6% from the stock's current price. View Analyst Price Targets for Amarin.

What is the consensus analysts' recommendation for Amarin?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last year. There are currently 1 sell rating, 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amarin.

What are Wall Street analysts saying about Amarin stock?

Here are some recent quotes from research analysts about Amarin stock:
  • 1. According to Zacks Investment Research, "Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies. " (11/7/2019)
  • 2. HC Wainwright analysts commented, "Our PT of $51 is based on equally weighted average of: (a) $47.99/share, as a 25x multiple of taxed and diluted FY29 GAAP EPS of $5.45 discounted back to and (b) an NPV of $53.14/share (discount rate 10%, growth rate 2%). Risks to our investment thesis and target price include: (1) Vascepa commercial ramp-up and/or peak sales not meeting our projections; and (2) further competitive disruption of the omega-3 market by branded drugs or generics and/ or OTC supplements beyond our model." (8/1/2019)
  • 3. Stifel Nicolaus analysts commented, "We are reiterating our Buy rating on AMRN shares after the company reported its 2Q19 financials, which came in at the higher end of its 7/2 pre-announcement; however, the key update is the fact management announced it believes an adcom is unlikely for Vascepa’s sNDA now given the close proximity to its PDUFA date. As we have discussed in previous notes, we believed the lack of an adcom would further de-risk Vascepa’s sNDA – so we see this update as an incremental positive and gets us more confident in sNDA approval. Given the high probability of approval, we believe investor focus is shifting to: (1) how Vascepa’s expanded label will read; (2) commercial execution in 2020 given its planned sales force expansion and whether or not 2020 Vascepa consensus sales estimates are too low; and (3) the potential timing and outcomes of Vascepa’s ongoing ANDA litigation." (7/31/2019)

Has Amarin been receiving favorable news coverage?

Media stories about AMRN stock have been trending somewhat negative recently, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Amarin earned a news sentiment score of -1.9 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Amarin.

Are investors shorting Amarin?

Amarin saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 55,640,000 shares, an increase of 10.3% from the September 30th total of 50,440,000 shares. Based on an average daily volume of 6,260,000 shares, the days-to-cover ratio is presently 8.9 days. Approximately 15.8% of the shares of the stock are sold short. View Amarin's Current Options Chain.

Who are some of Amarin's key competitors?

What other stocks do shareholders of Amarin own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amarin investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Square (SQ), Canopy Growth (CGC), Alibaba Group (BABA), Bank of America (BAC), Exelixis (EXEL), Netflix (NFLX) and Roku (ROKU).

Who are Amarin's key executives?

Amarin's management team includes the folowing people:
  • John F. Thero, President, Chief Executive Officer & Director
  • Derek Kalinowski, SVP-Manufacturing Operations
  • Michael W. Kalb, Chief Financial Officer & Senior Vice President
  • Steven B. Ketchum, Chief Scientific Officer & Senior Vice President
  • Craig B. Granowitz, Chief Medical Officer

Who are Amarin's major shareholders?

Amarin's stock is owned by a number of of institutional and retail investors. Top institutional investors include California Public Employees Retirement System (0.16%), Rhenman & Partners Asset Management AB (0.11%), Kornitzer Capital Management Inc. KS (0.09%), Catalyst Capital Advisors LLC (0.08%), Rational Advisors LLC (0.04%) and First Midwest Bank Trust Division (0.04%). Company insiders that own Amarin stock include Aaron Berg, David M Stack, John F Thero, Joseph S Zakrzewski, Joseph T Kennedy, Kristine Peterson, Lars Ekman, Michael Wayne Kalb and Steven B Ketchum. View Institutional Ownership Trends for Amarin.

Which major investors are selling Amarin stock?

AMRN stock was sold by a variety of institutional investors in the last quarter, including Tocqueville Asset Management L.P., First Midwest Bank Trust Division, Trellus Management Company LLC, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA, Tower Research Capital LLC TRC , Perkins Capital Management Inc. and Benjamin F. Edwards & Company Inc.. Company insiders that have sold Amarin company stock in the last year include Aaron Berg, David M Stack, John F Thero, Joseph S Zakrzewski, Joseph T Kennedy, Kristine Peterson, Lars Ekman, Michael Wayne Kalb and Steven B Ketchum. View Insider Buying and Selling for Amarin.

Which major investors are buying Amarin stock?

AMRN stock was purchased by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, Kornitzer Capital Management Inc. KS, Morse Asset Management Inc, Catalyst Capital Advisors LLC, Requisite Capital Management LLC, Rhenman & Partners Asset Management AB, Hayek Kallen Investment Management and Capital Advisors Ltd. LLC. View Insider Buying and Selling for Amarin.

How do I buy shares of Amarin?

Shares of AMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Amarin's stock price today?

One share of AMRN stock can currently be purchased for approximately $20.91.

How big of a company is Amarin?

Amarin has a market capitalization of $7.47 billion and generates $229.21 million in revenue each year. The biopharmaceutical company earns $-116,440,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis. View Additional Information About Amarin.

What is Amarin's official website?

The official website for Amarin is http://www.amarincorp.com/.

How can I contact Amarin?

Amarin's mailing address is Block C 77 Sir John Rogerson`s Quay Grand Canal Docklands, Dublin L2, Dublin 2. The biopharmaceutical company can be reached via phone at 353-1669-9020 or via email at [email protected]


MarketBeat Community Rating for Amarin (NASDAQ AMRN)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  713 (Vote Outperform)
Underperform Votes:  434 (Vote Underperform)
Total Votes:  1,147
MarketBeat's community ratings are surveys of what our community members think about Amarin and other stocks. Vote "Outperform" if you believe AMRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel